NasdaqGM - Nasdaq Real Time Price USD

Alpha Teknova, Inc. (TKNO)

1.7000

-0.0100

(-0.58%)

At close: April 25 at 4:00 PM EDT

Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financ

GlobeNewswire last month
Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market. Teknova will host a webcast and conference call on Monday, Ma

GlobeNewswire 2 months ago
Teknova Reports Third Quarter 2023 Financial Results

Raised $22.9 million of equity capital, paid down $10.0 million of long-term debtThird quarter 2023 total revenue was $8.2 million, down 24% from prior yearExpect 2023 revenue at the low end of previously announced guidance range of $37-40 million HOLLISTER, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecu

GlobeNewswire 5 months ago
Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023

HOLLISTER, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, following the close of market. Teknova will host a webcast and conference call on Thursday, November 9

GlobeNewswire 5 months ago
Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development

Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constructs and workflowsHOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched the

GlobeNewswire 6 months ago
Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility

HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 1,086,485 of its shares of common stock at a purchase price of $1.85 per share and concurrent private placement of an ag

GlobeNewswire 7 months ago
Teknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private Placement

HOLLISTER, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of up to 1,086,485 of its shares of common stock in a registered direct offering at a purchase price of $1.85 per share. In a concurrent privat

GlobeNewswire 7 months ago
Teknova Announces New Board Member, Martha J. Demski

HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who

GlobeNewswire 8 months ago
Sidoti Events, LLC’s Virtual August Micro-Cap Conference

Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change.

ACCESSWIRE 8 months ago
Teknova Reports Second Quarter 2023 Financial Results

Second quarter 2023 total revenue was $11.5 million, up 26% sequentiallyReceived certification of new state-of-the-art facility for production of GMP-grade productsCompany revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year HOLLISTER, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercializa

GlobeNewswire 8 months ago
Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical productionHOLLISTER, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the opening of their newest GMP-certified production facility, enabling bioproc

GlobeNewswire 8 months ago
Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market. Teknova will host a webcast and conference call on Thursday, August 10, 2023

GlobeNewswire 8 months ago
Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform

Results from the companies’ first collaboration show the successful achievement of more than 85% full AAV with 80-95% recoveries when pairing Sartorius BIA Separations’ monolithic purification platform with Teknova’s customized buffer formulationsHOLLISTER, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Sartorius BIA Separations, which is part of the international life science group Sartorius, today shared new data that demonstrates the ability to i

GlobeNewswire 9 months ago
Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process developmentHOLLISTER, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched the next set of rea

GlobeNewswire 9 months ago
Teknova to Participate in Upcoming Investor Conference

HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will present and host individual and small group meetings at the following upcoming investor conference: William Blair 43rd Annual Growth Stock ConferenceJune 6 - 8, 2023Chicago, IL Stephen Gunstream, Tekno

GlobeNewswire 10 months ago
Teknova Reports First Quarter 2023 Financial Results

First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™ Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial

GlobeNewswire 11 months ago
Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting

Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecksHOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the Company’s upcoming presentations at the American Society of Gene and Cell Therapy (AS

GlobeNewswire 11 months ago
Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023

HOLLISTER, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company has changed the timing of its previously announced first quarter 2023 financial results webcast and conference call to 5:30 p.m. Eastern Time on Wednesday, May 10, 2023. Participants can access the live web

GlobeNewswire 11 months ago
Teknova Launches Proprietary AAV-Tek™ Solutions Gene Therapy Product Line to Accelerate the Development of AAV Therapies

State-of-the-art screening kit – available for purchase today – could save months of process development time by helping gene therapy developers to identify the ideal buffer formulations for use during AAV downstream processingHOLLISTER, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launch

GlobeNewswire 11 months ago

Performance Overview

Return	TKNO	S&P 500
YTD	-54.42%	+5.84%
1-Year	-15.84%	+22.03%
3-Year	--	+17.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alpha Teknova, Inc. (TKNO)

Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Teknova Reports Third Quarter 2023 Financial Results

Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023

Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development

Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility

Teknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private Placement

Teknova Announces New Board Member, Martha J. Demski

Sidoti Events, LLC’s Virtual August Micro-Cap Conference

Teknova Reports Second Quarter 2023 Financial Results

Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform

Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

Teknova to Participate in Upcoming Investor Conference

Teknova Reports First Quarter 2023 Financial Results

Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting

Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023

Teknova Launches Proprietary AAV-Tek™ Solutions Gene Therapy Product Line to Accelerate the Development of AAV Therapies

Performance Overview